Targeting Akt signaling by inhibiting mTRO signaling has been shown to restore cancer responses to chemotherapy drugs [65, 66], and inhibition of both epidermal growth factor receptor (EGFR)/HER2 and MAPK signaling has been shown to result in growth inhibition and apoptosis of EGFR-expressing breast cancer cells [67]. Here, AKT1 is linked to breast carcinoma.